Towards shortening the Brief Addiction Monitor-Revised (BAM-R)

Blanchard, Brittany E.; Lynch, Kevin G.; Malte, Carol A.; Hawkins, Eric J.; DePhilippis, Dominick; Oslin, David W.; Saxon, Andrew J.

doi:10.1016/j.dadr.2023.100183

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BAM also has the benefit of software resources integrated into the EHR developed to support treatment administration at the VA and similar BAM assessment resources are also publicly available [ 50 ]. Five BAM items that demonstrated the greatest degree of change from a first to second assessment 30–60 days later were drug use, depression, craving, heavy alcohol use, and self-help involvement, but neither the five items alone nor the full BAM predicted outcomes [ 51 ].…”

Section: Introductionmentioning

confidence: 99%

Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus

Rush,

Gore-Langton,

Bart

et al. 2024

Addict Sci Clin Pract

Self Cite

View full text Add to dashboard Cite

Background The prevalence and associated overdose death rates from opioid use disorder (OUD) have dramatically increased in the last decade. Despite more available treatments than 20 years ago, treatment access and high discontinuation rates are challenges, as are personalized medication dosing and making timely treatment changes when treatments fail. In other fields such as depression, brief measures to address these tasks combined with an action plan—so-called measurement-based care (MBC)—have been associated with better outcomes. This workgroup aimed to determine whether brief measures can be identified for using MBC for optimizing dosing or informing treatment decisions in OUD. Methods The National Institute on Drug Abuse Center for the Clinical Trials Network (NIDA CCTN) in 2022 convened a small workgroup to develop consensus about clinically usable measures to improve the quality of treatment delivery with MBC methods for OUD. Two clinical tasks were addressed: (1) to identify the optimal dose of medications for OUD for each patient and (2) to estimate the effectiveness of a treatment for a particular patient once implemented, in a more granular fashion than the binary categories of early or sustained remission or no remission found in The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). Discussion Five parameters were recommended to personalize medication dose adjustment: withdrawal symptoms, opioid use, magnitude (severity and duration) of the subjective effects when opioids are used, craving, and side effects. A brief rating of each OUD-specific parameter to adjust dosing and a global assessment or verbal question for side-effects was viewed as sufficient. Whether these ratings produce better outcomes (e.g., treatment engagement and retention) in practice deserves study. There was consensus that core signs and symptoms of OUD based on some of the 5 DSM-5 domains (e.g., craving, withdrawal) should be the basis for assessing treatment outcome. No existing brief measure was found to meet all the consensus recommendations. Next steps would be to select, adapt or develop de novo items/brief scales to inform clinical decision-making about dose and treatment effectiveness. Psychometric testing, assessment of acceptability and whether the use of such scales produces better symptom control, quality of life (QoL), daily function or better prognosis as compared to treatment as usual deserves investigation.

show abstract

Section: Introductionmentioning

confidence: 99%